Analysis of T and NK cells immune response in Ipilimumab treated Melanoma patients
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1479-5876
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Analysis of T and NK cells immune response in Ipilimumab treated Melanoma patients ; volume:13 ; number:1 ; day:15 ; month:1 ; year:2015 ; pages:1-2 ; date:12.2015
Journal of translational medicine ; 13, Heft 1 (15.1.2015), 1-2, 12.2015
- Urheber
-
Tallerico, Rossana
- Beteiligte Personen und Organisationen
-
Cristiani, Costanza M.
Capone, Mariaelena
Madonna, Gabriele
Mallardo, Domenico
Simeone, Ester
Dominijanni, Andrea
Grimaldi, Antonio M.
Colucci, Francesco
Ascierto, Paolo A.
Carbone, Ennio
SpringerLink (Online service)
- DOI
-
10.1186/1479-5876-13-S1-O8
- URN
-
urn:nbn:de:1111-2016041451419
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 14.08.2025, 11:02 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Tallerico, Rossana
- Cristiani, Costanza M.
- Capone, Mariaelena
- Madonna, Gabriele
- Mallardo, Domenico
- Simeone, Ester
- Dominijanni, Andrea
- Grimaldi, Antonio M.
- Colucci, Francesco
- Ascierto, Paolo A.
- Carbone, Ennio
- SpringerLink (Online service)
Ähnliche Objekte (12)
Melanoma: the role of surgery in the era of new therapies
Adjuvant therapy of melanoma with interferon: lessons of the past decade
Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future?
Overall survival of patients with chemotherapy-naive advanced melanoma treated with ipilimumab 3 mg/kg in clinical trials
MISIPI study: Melanoma ImmunoScore evaluation in patients treated with IPIlimumab
Melanoma: A model for testing new agents in combination therapies
Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use
What have we learned from cancer immunotherapy in the last 3 years?
Combination therapy: the next opportunity and challenge of medicine
Automatic discovery of image-based signatures for ipilimumab response prediction in malignant melanoma
Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application
Systematic review of the use of granulocyte–macrophage colony-stimulating factor in patients with advanced melanoma
Melanoma: the role of surgery in the era of new therapies
Adjuvant therapy of melanoma with interferon: lessons of the past decade
Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future?
Overall survival of patients with chemotherapy-naive advanced melanoma treated with ipilimumab 3 mg/kg in clinical trials
MISIPI study: Melanoma ImmunoScore evaluation in patients treated with IPIlimumab
Melanoma: A model for testing new agents in combination therapies
Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use
What have we learned from cancer immunotherapy in the last 3 years?
Combination therapy: the next opportunity and challenge of medicine
Automatic discovery of image-based signatures for ipilimumab response prediction in malignant melanoma
Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application
Systematic review of the use of granulocyte–macrophage colony-stimulating factor in patients with advanced melanoma
Melanoma: the role of surgery in the era of new therapies
Adjuvant therapy of melanoma with interferon: lessons of the past decade
Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future?
Overall survival of patients with chemotherapy-naive advanced melanoma treated with ipilimumab 3 mg/kg in clinical trials
MISIPI study: Melanoma ImmunoScore evaluation in patients treated with IPIlimumab
Melanoma: A model for testing new agents in combination therapies
Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use
What have we learned from cancer immunotherapy in the last 3 years?
Combination therapy: the next opportunity and challenge of medicine
Automatic discovery of image-based signatures for ipilimumab response prediction in malignant melanoma
Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application